Capricor Therapeutics inc   (CAPR)

The company published Revenue of $0.959903 millions, in thefourth quarter of 2022 financial report

CAPR delivered fourth quarter of 2022 operating deficit of $-8.066345 millions

Published Mar 18 2023
Goran Soko / CSIMarket.com Contributer

Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons Capricor Therapeutics Inc has seen $0.959903 millions, in Revenue in the fiscal fourth quarter of 2022.

For the fiscal fourth quarter of 2022 Capricor Therapeutics Inc realized net loss of $-7.721 million, higher than $-6.191 million a year ago.

Capricor Therapeutics Inc announced loss of $-29.02 millions and Revenues of $2.55 millions in the financial period 2022.

Net loss per share has widen to $-1.18 from $-0.87 in prior financial year, while Revenue doubled by 941.85 % from $0.24 millions a year ago.

Capricor Therapeutics Inc is expected to report next financial recent numbers on May 10, 2023.

Capricor Therapeutics Inc's Effective Tax Rate

Capricor Therapeutics Inc's Price to sales ratio PS


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071